Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205252 | 0.86 | ALDH1A1 (0.35) | ALDH1A1ATMKDM4EMAPTNPC1 | |
| SCHEMBL717364 | 0.73 | CYP3A4 (0.35) | CYP3A4ALDH1A1MAPK1ATMABCG2 | |
| SCHEMBL789550 | 0.73 | CYP3A4 (0.35) | CYP3A4ALDH1A1MAPK1ATMABCG2 | |
| SCHEMBL3113441 | 0.73 | CYP3A4 (0.35) | CYP3A4ALDH1A1MAPK1ATMABCG2 | |
| SCHEMBL11789243 | 0.73 | MEN1 (0.37) | CYP3A4ALDH1A1MAPK1ABCG2MAPT | |
| SCHEMBL1096290 | 0.73 | CYP3A4 (0.35) | CYP3A4ALDH1A1MAPK1ATMABCG2 | |
| SCHEMBL4403183 | 0.72 | LMNA (0.41) | CYP3A4ALDH1A1MAPK1ATMMAPT | |
| SCHEMBL27673474 | 0.72 | TAAR1 (0.36) | CYP3A4ALDH1A1ATMKDM4EMAPT | |
| SCHEMBL8005199 | 0.69 | CYP3A4 (0.44) | CYP3A4ALDH1A1ATMABCG2KDM4E | |
| SCHEMBL596866 | 0.68 | PRKCI (0.37) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315714-A2 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1296952-A1 | BENZOYLPYRIDINE DERIVATIVE OR ITS SALT, FUNGICIDE CONTAINING IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION PROCESS AND INTERMEDIATE FOR PRODUCING IT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | SYNTEX (U.S.A.) LLC | 2002-04-18 | — | — | US | disclosed |
| WO-2002018348-A2 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002002527-A1 | BENZOYLPYRIDINE DERIVATIVE OR ITS SALT, FUNGICIDE CONTAINING IT AS AN ACTIVE INGREDIENT, ITS PRODUCTION PROCESS AND INTERMEDIATE FOR PRODUCING IT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | ADRB1, ADRA1B, ADRA1D | CYP3A4 422/4885ALDH1A1 211/4885MAPK1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.